Cellex Cell Professionals Achieves Major Milestone with 10,000 Autologous ATMP Batches

Cellex Cell Professionals Achieves Major Milestone with Over 10,000 Autologous ATMP Batches

Cellex Cell Professionals, known for its innovative approach in the field of cell therapy, has officially crossed the notable threshold of 10,000 autologous manufacturing batches for advanced therapy medicinal products (ATMPs). This achievement not only underscores the company's commitment to producing personalized therapies but also highlights its pivotal role as a reliable contract development and manufacturing organization (CDMO).

A Remarkable Achievement

On October 6, 2026, Cellex Cell Professionals announced this significant milestone, which represents their contributions to a total of 12 clinical and commercial partner programs. The journey towards producing each autologous batch requires a meticulous approach, as each batch is customized for individual patients. This customized care reflects Cellex’s dedication to quality and precision, as it involves various stages like collection of starting materials, production, quality assurance, logistics, and monitoring of chain-of-identity procedures. These steps must align flawlessly within deeply integrated processes, thereby making the accomplishment resonate beyond mere figures. Each batch signifies a distinct patient-specific operation meticulously crafted under stringent controls.

Insights from Dual Perspectives

Cellex’s expertise isn't limited to manufacturing alone; its experience as a developer provides unique insights into the numerous challenges partners face. Established prior to the formation of AvenCell in 2021, Cellex’s own CAR-T programs have informed their current practices and innovations. The challenges encountered in developing autologous and CRISPR/Cas-edited therapies empower Cellex to enhance its processes continually, ensuring that operational, regulatory, and scientific hurdles are met effectively.

Dr. Suvi Annala, the Vice President of Manufacturing, articulated the depth of understanding that has shaped their operations. "Every single one of these 10,000 batches was made specifically for an individual patient. Behind each batch lies a complex and highly coordinated process involving collection, manufacturing, testing, and logistics. This synchronization is crucial, as it directly impacts patients awaiting their treatments. Each partnership teaches us invaluable lessons that guide how we approach the subsequent projects."

Investment in Future Growth

Cellex remains committed to advancing its capabilities to embrace the increasing complexity inherent in cell therapy programs. Recent investments have flowed into expanding their infrastructure, including the establishment of new Grade B cleanrooms at their Cologne Ossendorf facility. By fortifying their foundation, Cellex aims to maintain its mission of delivering sophisticated cell therapies reliably and at scale to the healthcare market.

About Cellex Cell Professionals

Founded more than a decade ago, Cellex Cell Professionals specializes in CDMO services, focusing on both autologous and allogeneic products. The company collaborates closely with partners across the pharmaceutical, biotechnology, and academic sectors, providing support from preclinical and clinical development stages through to commercial manufacturing. Cellex's multidisciplinary team merges expertise in Good Manufacturing Practice (GMP) production with efficient cellular material collection and supply chain operations, ensuring quality and compliance along every step of the process.

For more information, visit Cellex's official website.